Apollomics Announces Presentation of Vebreltinib Data at the 2023 IASLC North America Conference on Lung Cancer (NACLC)
November 28, 2023 07:00 ET
|
Apollomics Inc.
FOSTER CITY, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to...
IO Biotech Announces 2023 Third Quarter Results
November 13, 2023 08:12 ET
|
IO Biotech
IO Biotech Announces 2023 Third Quarter Results
BioAtla Reports Third Quarter 2023 Financial Results and Highlights Recent Progress
November 07, 2023 16:01 ET
|
BioAtla, Inc.
Observed additional clinical responses and FDA feedback supports path forward for CAB-AXL-ADC (BA3011) non-small cell lung cancer (NSCLC) registrational study; detailed interim Phase 2 data to be...
Iovance Biotherapeutics Reports Third Quarter and Year-to-Date 2023 Financial Results and Corporate Updates
November 07, 2023 16:01 ET
|
Iovance Biotherapeutics, Inc.
FDA Priority Review of Biologics License Application (BLA) on Track for Lifileucel in Advanced Melanoma with Prescription Drug User Fee Act Action (PDUFA) Date of February 24, 2023 ...
ESMO 2023 Coverage: Get real time insights and analysis with DelveInsight
October 20, 2023 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Oct. 20, 2023 (GLOBE NEWSWIRE) -- ESMO 2023 Coverage: Get real time insights and analysis with DelveInsight The ESMO conference stands as a pivotal event in the oncology sphere,...
BioAtla Provides Guidance on Near-Term Milestones and Plans to Announce Third Quarter 2023 Financial Results and Business Update on November 7, 2023
October 10, 2023 07:30 ET
|
BioAtla, Inc.
Submitted abstract on CAB-AXL-ADC, BA3011, in non-small cell lung cancer (NSCLC) to the IASLC 2023 North America Conference on Lung Cancer; KOL event planned for December 4, 2023, following conclusion...
IO Biotech Announces New Data Related to its IO102-IO103 Therapeutic Cancer Vaccine Presented Today at the IASLC 2023 World Conference on Lung Cancer
September 12, 2023 08:05 ET
|
IO Biotech
Encouraging interim data support the potential of IO102-IO103 in combination with pembrolizumab as first-line treatment in non-small cell lung cancer NEW YORK, Sept. 12, 2023 (GLOBE NEWSWIRE) -- IO...
Allist and ArriVent Announce Interim Results from Ongoing Phase 1b Trial with Furmonertinib at the 2023 World Conference on Lung Cancer
September 10, 2023 01:30 ET
|
Arrivent Biopharma, Inc.
SHANGHAI, China, Sept. 10, 2023 (GLOBE NEWSWIRE) -- Allist Pharmaceuticals Co., Ltd. (“Allist”) and ArriVent Biopharma, Inc. (“ArriVent”) together announced that interim results from the Phase Ib,...
Catalyst Pharmaceuticals Announces Abstract on Lambert Eaton Myasthenic Syndrome (LEMS) to be Presented at the Upcoming IASLC 2023 World Conference of Lung Cancer
August 16, 2023 10:56 ET
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on...
IO Biotech Announces 2023 Second Quarter Results
August 11, 2023 08:30 ET
|
IO Biotech
Achieved significant enrollment milestone in pivotal Phase 3 trial of IO102-IO103 cancer vaccine in advanced melanoma; full enrollment anticipated by the end of 2023Initiated enrollment in three...